MSF alleges ViiV dragging feet on pediatric HIV therapies

Global humanitarian group Médecins Sans Frontières (MSF) has launched a scathing attack on joint venture ViiV Healthcare for “preventing children with HIV from getting child-appropriate formulations of a critical HIV medicine, dolutegravir.”

ViiV is majority-owned by Britain's GlaxoSmithKline (LSE: GSK), with US giant Pfizer NYSE: PFE) and Japan’s Shionogi (TYO: 4507) as minority partners.

The World Health Organization (WHO) recommends dolutegravir for adults and children from four weeks to ten years of age, as a better option over other therapies with worse side effects.